(d) We chose available PDX models to evaluate DTLL efficacy mainly due to the prominent difference in EGFR expression, but not HER‐2 expression; therefore, how the expression of HER2 might contribute to DTLL efficacy in pancreatic tumor needs to be further explored using more PDX models with different levels of HER2.46 The gene discussed is EGFR; the disease is pancreatic neoplasm.